Pharma’s obesity gold rush will have limits

from Viewsroom · host Reuters

Drugmakers Novo Nordisk and Eli Lilly are vying for a large slab of the weight loss medications market, which analysts reckon could be worth $100 bln by 2031. In this Viewsroom podcast, Breakingviews columnists discuss how investor optimism in a booming market is unwarranted. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published May 11, 2023

Embed this episode

Attribution link and audio player

Ready to play

Pharma’s obesity gold rush will have limits

0:00 14:11

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

Ozempic & Aesthetics: Reversing the Side Effects of Weight Loss Medications

Nov 24, 2025 ·11m

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Viewsroom?

This episode is 14 minutes long.

When was this Viewsroom episode published?

This episode was published on May 11, 2023.

Can I download this Viewsroom episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!